Find a Clinical Trial

Showing 41 - 50 of 51 Trials
  • Principal Investigator:

    Amer Assal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    II
    Patients who will be recieving immune effector cell (IEC) therapy for the treatment of their cancer are being asked to participate in this study. IEC can produce a harmful side effect called Cytokine Release Sydnrome (CRS). CRS involves a release of a large amount of proteins into the blood stream. This may cause changes in blood pressure and heartbeat, flu-like symptoms (nausea, fever, and chills), and/or affect lung/liver/kidney function. It may also cause certain brain-related symptoms, such as dizziness, weakness, confusion, difficulty speaking, and/or decreased brain function (possible...
  • Principal Investigator:

    Dawn L Hershman, MD

    Contact Number:

    Population:

    Adult

    Phase:

    NA
    - Are you 18 years old or older? - Do you have access to a smartphone, tablet, or computer to facilitate a video visit, or be willing to come into the hospital to borrow a tablet for the visit? - Did you receive a prescription for a new oral anti-cancer drug within 4 weeks taking part of this study? Are you Eligible? (Inclusion Criteria) Are you 18 years old or older? Do you have access to a smartphone, tablet, or computer to facilitate a video visit, or be willing to come into the hospital to borrow a tablet for the visit? Did you receive a prescription for a new oral anti-cancer drug within...
  • Principal Investigator:

    Grace A. Hillyer

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    II
    The purpose of this study is to compare two treatment programs for smoking cessation. Providing treatment medication at no cost to participants and providing additional counseling sessions could help more participants quit smoking and stay smoke free. There will be about 308 people taking part in this study. Are you Eligible? (Inclusion Criteria) Are you 18 year of age or older? Have you been diagnosed with cancer within the past 4 months? Have you had at least one puff of a cigarette in the past 30 days?
  • Principal Investigator:

    Mark N. Stein, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I/II
    The purpose of this study is to learn about the study drug RTX-240. This study is the first time RTX-240 will be used in people. Researchers will be studying the safety and effectivnes of RTX-240 in patients with certain types of cancer. The study will check if RTX-240 causes any changes in your health (or side effects), how well it may work at treating your cancer, how much needs to be given for it to work and how often it should be given. The study drug will be administered through IV and the time frame for the study will vary based on the response to treatment. The study drug is made of...
  • Principal Investigator:

    Richard D Carvajal, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    I
    This is a study of the experimental drug CS5001 developed by CStone pharmaceutical, in patients with advanced hematological and solid tumors. CS5001 will target certain receptors that are in high levels on cancer cells. This study will look at the anti-tumor activity of CS5001. CS5001 is not approved by any regulatory agency for the treatment of any condition. It is only available in clinical studies such as this one. To date, it has only been tested in animal studies. This is the first time that the study drug will be given to humans. Are you Eligible? (Inclusion Criteria) Are you at least...
  • Principal Investigator:

    Dawn L Hershman, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    NA
    Studies have shown that cancer patients and their spouses may be at high risk for financial problems because of the cost of cancer treatment. This study is being done to answer the following question: Can a financial navigation program help patients and their spouses understand and better manage the financial aspects of cancer care? A financial navigator is a person or team who work with patients and their families to help them reduce stress or hardship related to the cost of cancer treatment. Financial navigators help patients understand their out-of-pocket expenses and what their health...
  • Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to learn about the difficulties patients have with the amount of medication they are required to take and to see if a smart phone application can make that process easier for patients. Patients will be asked to use an application on their smartphone or tablet daily and to come to the clinic once a month for 3 months. Are you Eligible? (Inclusion Criteria) Do you have advanced or metastatic cancer, or a hematologic malignancy? Are you taking, or planning to take at least one oral anti-cancer drug? Do you have access to a mobile phone or tablet that can download...
  • Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    NCT Number:

    Population:

    Pediatrics

    Phase:

    I
    The purpose of this study is to learn more about the treatment of children and teenagers whose leukemia has come back (has relapsed) or has not gone away after other treatments (is refractory). Participants will receive the study drug, called carfilzomib in combination with standard chemotherapy, that are dexamethasone, daunorubicin , vincristine and PEG-asparaginase (VXLD backbone). The study consist of 4 periods: Screening Period, Treatment Period, End of Study Period, and Long-term Follow-up Period. Participants with stable disease or better response at the end of the Induction Cycle will...
  • Principal Investigator:

    Andrew H Lipsky, MD

    Contact Number:

    NCT Number:

    Population:

    Adult

    Phase:

    III
    This research study is being done to test the effectivenss and safety of an investigational treatment called LOXO-305. LOXO-305 is an investigational (or experimental) drug that may treat certain cancers like leukemia and lymphomas, including, mantle cell lymphoma (MCL). These cancers are dependent on or “addicted to” a protein made by the cancers called “BTK”. LOXO-305 is a “BTK inhibitor”—it is designed to block both normal and mutated forms of BTK in these cancers. Are you Eligible? (Inclusion Criteria) At least 18 years of age Able to swallow oral...
  • Principal Investigator:

    Nobuko Hijiya, MD

    Contact Number:

    NCT Number:

    Population:

    Pediatrics

    Phase:

    I
    This is a Phase 1 multicenter study of Vincristine Sulfate Liposome Injection (Marqibo) in combination with standard chemotherapy drugs. The study treatment is considered experimental because it is not approved by the United States (US) Food and Drug Administration (FDA) for treating children and young adults with acute lymphoblastic leukemia (ALL) which has come back after treatment. The purpose of this study is to evaluate the side effects of giving Marqibo with other standard chemotherapy drugs in children with relapsed ALL. Another goal is to measure how effective Marqibo given with other...